Breast Biopsy Market Analysis: Growth, Size, Share & Future Trends (2024-2029) 

The market report offers a detailed analysis segmented by Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others); by Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy); by Technique (Image Guided Biopsy, Liquid Biopsy); by Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).

Outlook 

• The breast biopsy market is estimated to be at USD 2,290.11 Mn in 2024 and is anticipated to reach USD 3,300.23 Mn in 2029. 

• The breast biopsy market is registering a CAGR of 7.58% during the forecast period 2024-2029. 

• The breast biopsy market is expanding due to increasing breast cancer cases, rising awareness of early detection, and an increasing number of breast cancer screening programs. The growing adoption of advanced biopsy systems and real-time imaging solutions is driving market growth.  

Request a free sample. 

Ecosystem 

• The participants in the global breast biopsy industry are always developing their strategies to preserve a competitive advantage. 

• Smaller companies are also entering the market, intensifying competition through the development of portable and cost-effective biopsy devices. 

• Several important entities in the breast biopsy market include Hologic, Inc.; Danaher Corp.; Becton, Dickinson and Co.; Qiagen N.V.; Argon Medical Devices, Inc.; and others. 

Ask for customization. 

Findings 

Attributes	Values
Historical Period	2018-2022
Base Year	2023
Forecast Period	2024-2029
Market Size (2024)	USD 2,290.11 Mn
Market Size (2029)	USD 3,300.23 Mn
Growth Rate	7.58% CAGR from 2024 to 2029
Key Segments	Type (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others); Procedure (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy); Technique (Image Guided Biopsy, Liquid Biopsy); Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa)
Key Vendors	Hologic, Inc.; Danaher Corp.; Becton, Dickinson and Co.; Qiagen N.V.; Argon Medical Devices, Inc.
Key Countries	The US; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa
Largest Market	North America

Get a free quote. 

Trends  

• Liquid Biopsy Advancements: Liquid biopsy advancements have revolutionized breast cancer detection by using circulating tumor DNA (ctDNA) from a patient’s blood, which offers a non-invasive alternative to traditional biopsies. This method allows for real-time monitoring of cancer progression and treatment response. For example, Guardant360 has shown high accuracy in identifying breast cancer mutations, while GRAIL’s Galleri test has demonstrated potential in detecting breast cancer at earlier stages, which could lead to improved outcomes. 

• Robotic-Assisted Breast Biopsy Systems: Robotic-assisted breast biopsy systems are enhancing the precision and accuracy of biopsy procedures by improving needle placement, particularly in hard-to-reach areas. These systems reduce human error and provide better access to deep or small lesions. For instance, the Mammotome Revolve system integrates real-time imaging to ensure accurate targeting, and Hologic’s Brevera biopsy system allows for immediate verification of collected samples, which minimizes the need for multiple insertions. 

• Vacuum-Assisted Biopsy (VAB) Improvements: Vacuum-assisted biopsy (VAB) improvements have made this minimally invasive procedure more efficient and patient-friendly. VAB systems, such as BD’s EnCor Enspire, now incorporate real-time imaging and enhanced portability, which makes them suitable for a wide range of clinical settings. Additionally, innovations like Hologic’s Affirm prone biopsy system have reduced procedure times and improved patient comfort while still delivering precise and reliable tissue sampling. 

Speak to analyst. 

Catalysts 

• Increasing Number of Breast Cancer Screening Programs: The growing number of government and private screening initiatives is boosting demand for breast biopsy procedures. Programs like India’s National Program for Prevention and Control of Cancer and Breast Screen Australia have expanded access to early detection, driving biopsy utilization as more suspicious findings are identified. 

• Growing Incidence of Breast Cancer: Rising breast cancer cases, particularly in developing countries, are accelerating the need for diagnostic biopsies. The World Health Organization (WHO) reported a sharp rise in breast cancer diagnoses globally, with over 2.3 million cases in 2020, which leads to increased demand for accurate and early biopsy procedures. 

• Growing Awareness of Early Detection: Public awareness campaigns are leading to earlier diagnosis and treatment of breast cancer, driving biopsy market growth. Initiatives like Susan G. Komen’s Breast Cancer Awareness Month have heightened focus on the importance of early detection, which resulted in more women opting for screening and follow-up biopsies when abnormalities are detected. 

Inquire before buying. 

Restraints 

• Risk of Infections Associated with Biopsy Needles: Biopsy procedures carry a risk of infection at the needle insertion site, which can complicate patient recovery and deter some individuals from undergoing the procedure. Studies have shown that infections, although rare, can occur, particularly in immunocompromised patients, which leads to concerns about the safety of frequent biopsies. 

• Stringent Regulatory Approval Procedures: Obtaining regulatory approval for new biopsy technologies and devices is a lengthy and complex process. Regulatory bodies like the FDA require extensive clinical trials and safety data, which delays the introduction of innovative biopsy solutions to the market and increases costs for manufacturers. 

• Shortage of Skilled Professionals and Inadequate Healthcare Infrastructure: A shortage of trained radiologists and healthcare professionals in certain regions, especially in developing countries, hinders the accessibility of breast biopsy procedures. Additionally, inadequate healthcare infrastructure in rural or low-income areas limits the availability of advanced biopsy techniques, which delays early diagnosis and treatment. 

Personalize this research. 

Hotspot 

Explore purchase options. 

Table of Contents 

1.       Introduction         1.1.    Research Methodology         1.2.    Scope of the Study  2.       Market Overview / Executive Summary         2.1.    Global Breast Biopsy Market (2018 – 2022)         2.2.    Global Breast Biopsy Market (2023 – 2029)  3.       Market Segmentation         3.1.    Global Breast Biopsy Market by Type                3.1.1.    Biopsy Needles                3.1.2.    Guidance Systems                3.1.3.    Biopsy Tables                3.1.4.    Localization Wires                3.1.5.    Assay Kits                3.1.6.    Liquid Biopsy Instruments                3.1.7.    Others         3.2.    Global Breast Biopsy Market by Procedure                3.2.1.    Needle Breast Biopsy                3.2.2.    Open Surgical Breast Biopsy                3.2.3.    Liquid Breast Biopsy         3.3.    Global Breast Biopsy Market by Technique                3.3.1.    Image Guided Biopsy                3.3.2.    Liquid Biopsy         3.4.    Global Breast Biopsy Market by Application                3.4.1.    Early Cancer Screening                3.4.2.    Therapy Selection                3.4.3.    Treatment Monitoring                3.4.4.    Recurrence Monitoring  4.       Regional Segmentation         4.1.    North America                4.1.1.    The US                4.1.2.    Canada                4.1.3.    Mexico         4.2.    South America                4.2.1.    Brazil                4.2.2.    Argentina                4.2.3.    Colombia                4.2.4.    Chile                4.2.5.    Rest of South America         4.3.    Asia Pacific                4.3.1.    China                4.3.2.    India                4.3.3.    Japan                4.3.4.    South Korea                4.3.5.    Rest of Asia Pacific         4.4.    Europe                4.4.1.    The UK                 4.4.2.    Germany                4.4.3.    Italy                4.4.4.    France                4.4.5.    Spain                4.4.6.    Rest of Europe         4.5.    The Middle East                4.5.1.    Turkey                4.5.2.    UAE                4.5.3.    Saudi Arabia                4.5.4.    Rest of the Middle East         4.6.    Africa                4.6.1.    Egypt                4.6.2.    South Africa                4.6.3.    Rest of Africa  5.       Value Chain Analysis of the Global Breast Biopsy Market  6.       Porter Five Forces Analysis         6.1.    Threats of New Entrants         6.2.    Threats of Substitutes         6.3.    Bargaining Power of Buyers         6.4.    Bargaining Power of Suppliers         6.5.    Competition in the Industry  7.       Trends, Drivers and Challenges Analysis         7.1.    Market Trends         7.1.1.    Market Trend 1         7.1.2.    Market Trend 2         7.1.3.    Market Trend 3         7.2.    Market Drivers         7.2.1.    Market Driver 1         7.2.2.    Market Driver 2         7.2.3.    Market Driver 3         7.3.    Market Challenges         7.3.1.    Market Challenge 1         7.3.2.    Market Challenge 2         7.3.3.    Market Challenge 3  8.       Opportunities Analysis         8.1.    Market Opportunity 1         8.2.    Market Opportunity 2         8.3.    Market Opportunity 3  9.       Competitive Landscape         9.1.    Hologic, Inc.         9.2.    Danaher Corp.         9.3.    Becton, Dickinson and Co.         9.4.    Qiagen N.V.         9.5.    Argon Medical Devices, Inc.         9.6.    Company 6         9.7.    Company 7         9.8.    Company 8         9.9.    Company 9         9.10.  Company 10

Know the research methodology. 

Breast Biopsy Market – FAQs 

1.  What is the current size of the breast biopsy market? 

Ans. In 2024, the breast biopsy market size is USD 2,290.11 Mn. 

2.  Who are the major vendors in the breast biopsy market?  

Ans. The major vendors in the breast biopsy market are Hologic, Inc.; Danaher Corp.; Becton, Dickinson and Co.; Qiagen N.V.; Argon Medical Devices, Inc. 

3.  Which segments are covered under the breast biopsy market segments analysis?  

Ans. The breast biopsy market report offers in-depth insights into Type, Procedure, Technique, Application, and Geography.